Lydia R.
- Country
- France
- Department
- Hématologie Clinique
Research Overview
- Phase III Randomized Open-Label Multicenter Trial of Ruxolitinib vs. Hydroxycarbamide or Peginterferon Alfa-2a in High-Risk Polycythemia Vera Patients
- Evaluation of Treatment-Free Remission in Chronic Myeloid Leukemia Patients Following Second Discontinuation of Dasatinib Therapy
- Evaluation of Pioglitazone and Avelumab in Combination with Tyrosine Kinase Inhibitors for Chronic Phase Chronic Myelogenous Leukemia in Cytogenetic Response
Data & Insights
Has run more than one trial at 37 of 88 partner sites.
Specializations
Chronic Myeloid Leukemia Management
The investigator specializes in treating chronic myeloid leukemia (CML), with particular focus on developing innovative treatment discontinuation strategies and exploring treatment-free remission approaches.
- Treatment-free remission protocols
- TKI discontinuation strategies
- Advanced CML management
The research extends to both chronic phase and advanced stages of CML, including accelerated phase and blast crisis.
Myeloproliferative Disorders
Expertise in treating various myeloproliferative neoplasms, with specific interest in therapeutic approaches for polycythemia vera and essential thrombocythemia.
- Novel therapeutic combinations
- Thrombosis prevention strategies
- JAK2V617F-positive conditions
Focuses on developing targeted treatments and preventive measures for thromboembolic complications in these disorders.
Innovative Therapeutic Approaches
Investigates novel therapeutic combinations including tyrosine kinase inhibitors and explores alternative treatment strategies for hematologic malignancies.
- Combination therapy development
- Drug sequencing optimization
- Molecular response monitoring
Specializes in adapting treatment protocols to achieve optimal therapeutic outcomes in blood disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.